Magenta Therapeutics Inc. (MGTA)
NASDAQ: MGTA
· Real-Time Price · USD
0.70
-0.06 (-7.69%)
At close: Sep 11, 2023, 10:00 PM
Magenta Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.16M | 6.24M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -33.18M | -82.61M | -29.9M | -22.2M | -15.76M | -7.38M | 3.88M | -21.73M | -17.25M | -18.08M | -23.83M | -20.14M | -18.25M | -17.61M | -18.7M |
Interest Income | 3.79M | 9.29M | 4.45M | 4.71M | 1.03M | 4.09M | 2.96M | n/a | 1.19M | 812K | 884K | 848K | 818K | n/a | 1.21M |
Pretax Income | -29.51M | -37.75M | -25.17M | -17.61M | -14.76M | -3.28M | -29.17M | -20.18M | -16.06M | -17.27M | -22.95M | -19.29M | -17.43M | -16.93M | -17.49M |
Net Income | -29.51M | -40.71M | -25.17M | -17.61M | -14.76M | -3.28M | -26.21M | -23.06M | -17.25M | -17.27M | -22.95M | -19.29M | -17.43M | -16.93M | -17.49M |
Selling & General & Admin | 7.34M | 4.82M | 6.53M | 6M | 8.72M | 5.32M | 6.13M | 5.94M | 6.05M | 6.48M | 7.29M | 7.03M | 7.45M | 6.48M | 6.97M |
Research & Development | 27M | 67.01M | 25.54M | 18.07M | 7.96M | 139K | 8M | 15.79M | 11.2M | 11.6M | 16.55M | 13.11M | 10.79M | 11.13M | 11.73M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 34.34M | 71.83M | 32.07M | 24.07M | 16.68M | 5.46M | 14.13M | 21.73M | 17.25M | 18.08M | 23.83M | 20.14M | 18.25M | 17.61M | 18.7M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.19M | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 71.83M | n/a | n/a | 16.68M | 5.46M | 14.13M | 21.73M | 17.25M | 18.08M | 23.83M | 20.14M | 18.25M | 17.61M | 18.7M |
Income Tax Expense | n/a | 8.97M | n/a | n/a | n/a | n/a | -2.96M | 2.89M | 1.19M | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 3.91M | 3.91M | 3.91M | 3.91M | 3.91M | 3.19M | 3.19M | 3.12M | 3.12M | 58.82M | 58.8M | 58.79M | 58.58M | 53.71M | 48.57M |
Shares Outstanding (Diluted) | 3.91M | 3.91M | 3.91M | 3.91M | 3.91M | 3.19M | 3.19M | 3.12M | 3.12M | 58.82M | 58.8M | 58.79M | 58.58M | 53.71M | 48.57M |
EPS (Basic) | -7.55 | 13.02 | -6.44 | -4.51 | -3.78 | -1.03 | -8.21 | -7.38 | -5.53 | -0.29 | -0.39 | -0.33 | -0.3 | -0.32 | -0.36 |
EPS (Diluted) | -7.55 | 13.02 | -6.44 | -4.51 | -3.78 | -1.03 | -8.21 | -7.38 | -5.53 | -0.29 | -0.39 | -0.33 | -0.3 | -0.32 | -0.36 |
EBITDA | -33.18M | -35.96M | -29.9M | -22.2M | -15.76M | -3.54M | 4.3M | -21.27M | -16.78M | -18.08M | -22.62M | -20.14M | -17.71M | -17.13M | -18.22M |
EBIT | n/a | n/a | n/a | n/a | -15.76M | -7.38M | 3.88M | -23.06M | -14.87M | n/a | -23.83M | n/a | -18.25M | -17.61M | -18.7M |
Depreciation & Amortization | n/a | -4.22M | n/a | n/a | -39.59K | 3.84M | 421K | 466K | 471K | -222K | 1.21M | 535K | 532K | 479K | 474K |